Iovance Biotherapeutics, Inc. (LON:0JDK)
United Kingdom · Delayed Price · Currency is GBP · Price in USD | Market Cap | 2.63B +278.8% |
| Revenue (ttm) | 285.46M +51.3% |
| Net Income | -166.11M |
| EPS | -0.38 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 53,529 |
| Open | 8.20 |
| Previous Close | 8.67 |
| Day's Range | 7.95 - 8.41 |
| 52-Week Range | 2.09 - 17.25 |
| Beta | 0.84 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients w... [Read more]
Financial Performance
In 2025, Iovance Biotherapeutics's revenue was $263.50 million, an increase of 60.60% compared to the previous year's $164.07 million. Losses were -$390.98 million, 5.05% more than in 2024.
Financial numbers in USD Financial StatementsNews
Iovance price target raised to $12 from $8 at Citizens
Citizens raised the firm’s price target on Iovance (IOVA) to $12 from $8 and keeps an Outperform rating on the shares. Iovance reported Q3 results and highlighted a robust clinical…
Iovance price target raised to $19 from $18 at Barclays
Barclays raised the firm’s price target on Iovance (IOVA) to $19 from $18 and keeps an Overweight rating on the shares.
Iovance Biotherapeutics Earnings Call Transcript: Q3 2026
Q3 revenue set a record at ~$122M, with ~60% gross margin and reaffirmed FY2026 guidance of $410M–$420M. Amtagvi adoption and the ATC network expanded as clinical programs advanced toward planned submissions.
Iovance Biotherapeutics Earnings release: Q3 2026
Iovance Biotherapeutics released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Iovance Biotherapeutics Quarterly report: Q3 2026
Iovance Biotherapeutics has published its Q3 2026 quarterly earnings report on November 5, 2026.
Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates
Total Revenue Increased ~80% and U.S. Amtagvi Revenue Increased ~77% Year-over-Year, and Gross Margin Increased to ~60% 24.6% Objective Response Rate (ORR) in 69 Patients with Non-Squamous Metastatic...
Iovance price target raised to $8 from $7 at UBS
UBS raised the firm’s price target on Iovance (IOVA) to $8 from $7 and keeps a Neutral rating on the shares ahead of its Q3 results. The firm notes the…
Iovance price target lowered to $9 from $11 at Baird
Baird lowered the firm’s price target on Iovance (IOVA) to $9 from $11 and keeps a Neutral rating on the shares. The firm updated its model following its NSCLC data…
Iovance reports updated IOV-LUN-202 results for lifileucel in lung cancer
Iovance (IOVA) Biotherapeutics announced updated results from Cohorts 1 and 2 of its Phase 2 IOV-LUN-202 trial and a biomarker-enriched precision tumor infiltrating lymphocyte, or TIL, strategy for li...
Iovance Biotherapeutics Transcript: Study update
Lifileucel showed a ~25% ORR in 69 previously treated NSCLC patients, with 59.1% ORR in a biomarker-enriched subgroup. POSITILITY enrollment is set to begin in November 2026, while OPTILISM is planned for 2027.
Iovance Biotherapeutics Slides: Study update
Iovance Biotherapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 29, 2026.
Iovance Biotherapeutics Press release: Study update
Iovance Biotherapeutics issued a press release on October 29, 2026, disclosing material business information to investors.
Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)
24.6% Objective Response Rate (ORR) in 69 Patients with Non-Squamous mNSCLC, Consistent with Previously Reported Results IOV-LUN-202 Cohorts 1 and 2 Are Completing Enrollment and Support a Planned Sup...
Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy
Live Webcast at 8:30 a.m. ET on Thursday, October 29, 2026 PHILADELPHIA, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on i...
Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026
PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumo...
Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026
50% Confirmed Objective Response Rate (ORR) with All Responses Ongoing in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 Unprecedented Efficacy in Both Refracto...
Iovance’s Amtagvi shows durability in 1L melanoma, says Jefferies
Updated Phase II data from Iovance (IOVA) for Amtagvi plus PD-1 in first-line melanoma showed durable PFS competitive with approved combinations, supporting the ongoing Phase III TILVANCE-301 and pote...
Iovance says one-time lifileucel showed 29.2% complete response rate
Iovance (IOVA) announced that one-time lifileucel combined with pembrolizumab demonstrated a 62.5% objective response rate and a 29.2% complete response rate, with median overall survival not reached ...
Iovance drops 3% to $13.67 after new melanoma data
10:23 EDT Iovance (IOVA) drops 3% to $13.67 after new melanoma data
Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma
62.5% Confirmed Objective Response Rate (ORR) and 29.2% Complete Response (CR) Rate in Final Phase 2 Analysis Median Overall Survival (OS) Not Reached at More than 4 Years of Median Follow-up Oral Pre...
Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026
Iovance Advances TIL Cell Therapy into a New Chapter in Solid Tumor Treatment Two Oral Presentations to Showcase Deep, Durable Responses with TIL Cell Therapy in Frontline Melanoma and Previously Trea...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PHILADELPHIA, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering nov...
Iovance Biotherapeutics price target raised to $18 from $15 at Barclays
Barclays analyst Etzer Darout raised the firm’s price target on Iovance Biotherapeutics (IOVA) to $18 from $15 and keeps an Overweight rating on the shares. The firm adjusted targets in…